🧬 Aging Wiki

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

7 min read

⚠️ Auto-extracted by Claude on 2026-05-31. The NEJM full text is paywalled and no local PDF is available in a local paper archive (download status: pending). Bibliographic fields (authors, volume, issue, pages, PMID) were verified against Crossref and PubMed efetch on 2026-05-31. All quantitative endpoint values (HRs, CIs, p-values, secondary endpoints, subgroup analyses) are sourced from the user-provided verified-fact set and the JAMA Cardiology post-hoc abstract (doi:10.1001/jamacardio.2026.0767) — they must be re-confirmed against the primary NEJM manuscript and supplementary appendix before this page is marked verified. no-fulltext-access

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT; Nicholls et al. 2025)

TL;DR

SURPASS-CVOT was a double-blind, active-comparator RCT in 13,165 adults with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), randomized to tirzepatide (dual GIP/GLP-1 receptor agonist) vs dulaglutide (pure GLP-1 agonist) for a median of 46.9 months across 640 centers globally. The pre-specified primary endpoint — 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke) — met non-inferiority (HR 0.92; p=0.003 for non-inferiority) but did not meet the pre-specified superiority threshold (p=0.09). A post-hoc expansion to a 6-component cardiorenal composite gave HR 0.84 (95% CI ~0.79–0.90), which is hypothesis-generating but not a registered primary result. The correct reading of this trial is: tirzepatide is non-inferior to an active GLP-1 RA on pre-specified cardiovascular outcomes; superiority in the cardiovascular domain was not demonstrated in the primary analysis.

Study design

ParameterValue
Trial registrationNCT04255433 (ClinicalTrials.gov)
DesignRandomized, double-blind, active-comparator-controlled
ComparatorDulaglutide (Trulicity; GLP-1 agonist)
InterventionTirzepatide (Mounjaro/Zepbound; dual GIP/GLP-1 agonist)
PopulationAdults with T2D + established ASCVD
N randomized13,165
Centers640 (global)
Median follow-up46.9 months
Primary endpoint3-point MACE (CV death + non-fatal MI + non-fatal stroke); first occurrence
Superiority thresholdPre-specified; conventional p<0.05 two-sided

The active-comparator design against dulaglutide (rather than placebo) is a critical feature: both arms are expected to produce cardiovascular benefit over placebo (established by the GLP-1 class in LEADER, SUSTAIN-6, REWIND, etc.). The question tested here is whether tirzepatide’s additional GIP agonism confers incremental benefit over GLP-1 agonism alone.

Primary endpoint result

Tirzepatide: ~12% experienced the 3-point MACE composite. Dulaglutide: ~13% experienced the 3-point MACE composite. HR 0.92 (95% CI and full p-value pending PDF verification). Non-inferiority p=0.003 (non-inferiority margin pre-specified). Superiority p=0.09 (pre-specified threshold not crossed) 1.

Interpretation: Non-inferiority means tirzepatide is not meaningfully worse than dulaglutide for 3-point MACE. Superiority was not established. The trial should not be cited as evidence that tirzepatide is cardiovascularly superior to any GLP-1 RA on the basis of the primary registered analysis. This matters for the longevity-medicine claim that tirzepatide is preferable to semaglutide on cardiovascular grounds — SURPASS-CVOT does not support that specific claim on its primary pre-registered endpoint. contradictory-evidence

Post-hoc 6-component cardiorenal composite

A post-hoc exploratory analysis (Nissen SE et al. 2026, JAMA Cardiology; doi:10.1001/jamacardio.2026.0767) expanded the primary composite to 6 components by adding hospitalization for heart failure, coronary revascularization, all-cause death, and a renal composite. This yielded HR 0.84 (95% CI ~0.79–0.90; ~16% relative reduction) in favor of tirzepatide 2.

Critical framing: This is a post-hoc analysis, conducted after the pre-specified primary endpoint did not meet superiority. The endpoint expansion was not pre-registered for this trial. While the result is plausible given tirzepatide’s additional GIP-mediated effects on weight, renal function, and metabolic parameters, it cannot be used to override the pre-registered primary result. Standard evidence-grading treats post-hoc endpoint expansions as hypothesis-generating, not confirmatory. The appropriate follow-up would be a prospectively registered trial with the 6-component composite as the primary endpoint.

Key secondary and exploratory findings

The following are based on the user-provided brief and post-hoc publication abstract; full secondary-endpoint table requires PDF verification.

  • Weight loss: Tirzepatide produced greater body-weight reduction than dulaglutide (magnitude pending PDF verification; consistent with SURPASS-1/2/3/5 data showing ~10–15 kg advantage over dulaglutide at maximal doses). needs-pdf-verification
  • Kidney outcomes: Pre-specified exploratory kidney analysis published separately (Zoungas S et al. 2026, Lancet Diabetes & Endocrinology; doi:10.1016/S2213-8587(26)00032-X) examined major kidney events; results pending full-text review.
  • Glycemic control: Tirzepatide expected to show superior HbA1c reduction (established in SURPASS program); actual CVOT data pending PDF verification. needs-pdf-verification

Why this trial matters for aging biology

Type-2-diabetes is both a metabolic disease and a driver of accelerated biological aging. Chronic insulin resistance and hyperglycemia engage several hallmarks of aging — particularly deregulated-nutrient-sensing (mTORC1 hyperactivation, AMPK suppression), mitochondrial-dysfunction (from glucolipotoxicity), and chronic-inflammation (via NLRP3, NFκB, and advanced glycation end-products). GLP-1/GIP receptor agonists reduce ASCVD risk through a combination of weight loss, glycemic improvement, blood-pressure reduction, and probable direct vascular effects. Whether they modulate biological-age clocks is an active research question not answered by this trial.

The trial population (established ASCVD + T2D) represents a high-accelerated-aging cohort. SURPASS-CVOT demonstrates that tirzepatide is at minimum non-inferior on hard cardiovascular endpoints to an established GLP-1 RA, which is a prerequisite for deployment in aging-biology protocols targeting cardiometabolic risk.

Head-to-head context: tirzepatide vs semaglutide

This trial compares tirzepatide to dulaglutide, not semaglutide (the most commonly used GLP-1 RA in longevity contexts). No direct head-to-head cardiovascular-outcomes RCT of tirzepatide vs semaglutide exists as of May 2026. Inferences about tirzepatide vs semaglutide for cardiovascular benefit require indirect comparison through GLP-1 class CVOT data (LEADER, SUSTAIN-6, SELECT) and the SURPASS-CVOT results — a methodologically weak basis for strong preference claims. contradictory-evidence

The longevity-influencer-sphere claim that SURPASS-CVOT justifies choosing tirzepatide over semaglutide rests on:

  1. The post-hoc 6-component composite result — which is hypothesis-generating, not confirmatory.
  2. The indirect inference that the directional (but non-significant) HR 0.92 trend will be replicated in a larger or longer trial.

Neither inference is well-supported by standard cardiovascular-evidence appraisal. The honest read is: tirzepatide is non-inferior to an active GLP-1 RA; whether it exceeds semaglutide specifically on pre-registered hard endpoints is unanswered.

Extrapolation to aging biology

DimensionStatusNotes
Pathway conserved in humans?yesTrial is in humans
Phenotype (MACE reduction) conserved across aging subgroups?partialNo published age-stratified subgroup data available as of 2026-05-31; needs-pdf-verification
Replicated for tirzepatide vs dulaglutide?yes (non-inferiority confirmed)Superiority not replicated/established

Strengths

  • Large n=13,165 across 640 global centers; adequately powered for the non-inferiority claim
  • Active-comparator design (vs dulaglutide) is methodologically rigorous; rules out placebo effect
  • Double-blind; long median follow-up (~47 months)
  • Published in NEJM (peer-reviewed); pre-registered (NCT04255433)
  • Companion kidney-outcomes paper published simultaneously in Lancet Diabetes & Endocrinology (Zoungas 2026)

Limitations

  • Superiority not met on the primary pre-registered endpoint — the primary claim this trial was powered to test was not achieved
  • Post-hoc composite expansion carries all the usual limitations: multiple testing, endpoint cherry-picking risk, not pre-registered
  • No semaglutide arm — cannot generalize to the tirzepatide-vs-semaglutide question directly
  • Full-text PDF not yet verified — all quantitative claims flagged above require cross-check against the primary manuscript + supplementary appendix
  • Both agents are GLP-1 RAs; the incremental cardiometabolic benefit attributable to GIP agonism specifically is difficult to isolate mechanistically in a CVOT design

Gaps

  • Mechanism distinguishing tirzepatide’s directional CV benefit from dulaglutide not established in this trial no-mechanism
  • Age-stratified subgroup data (relevant to aging-biology interpretation) pending PDF review needs-pdf-verification
  • Head-to-head superiority vs semaglutide on pre-registered MACE endpoints: unanswered needs-replication

Cross-references

  • tirzepatide — compound page (dual GIP/GLP-1 agonist; this is the index cardiovascular CVOT)
  • semaglutide — related GLP-1 agonist; see SELECT trial for semaglutide MACE data in non-diabetic obese subjects
  • glp1-agonists — class page; SURPASS-CVOT adds to the class-level cardiovascular evidence base
  • type-2-diabetes — the enrolled population; T2D is an accelerated-aging context
  • deregulated-nutrient-sensing — primary aging-hallmark intersection
  • chronic-inflammation — secondary hallmark intersection via ASCVD/T2D inflammatory burden

Footnotes

Footnotes

  1. doi:10.1056/NEJMoa2505928 · Nicholls SJ et al. · N Engl J Med 2025;393(24):2409–2420 · PMID 41406444 · rct · n=13,165 · double-blind active-comparator · pre-registered NCT04255433 · model: adults with T2D + established ASCVD · primary endpoint 3-point MACE: HR 0.92, non-inferiority p=0.003, superiority p=0.09 (not met) ↩

  2. doi:10.1001/jamacardio.2026.0767 · Nissen SE, Wolski K, D’Alessio D et al. · JAMA Cardiology 2026 (published online March 28, 2026) · post-hoc analysis of SURPASS-CVOT · 6-component cardiorenal composite: HR 0.84 (95% CI ~0.79–0.90) · post-hoc endpoint expansion; hypothesis-generating only · not pre-registered for this analysis ↩

Graph View

Backlinks